Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyperexcitability. It also binds to CRMP‑2, a protein involved in neuronal development, which further modulates neuronal excitability and helps prevent seizure propagation.

The specific dose and infusion rate of lacosamide are determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function, and response to therapy. Dosing should follow the approved prescribing information and be individualized for each patient.

Safety data for lacosamide in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Clinicians should carefully weigh the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing patients.

To order Lacosamide Fresenius Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lacosamide has a unique mechanism that enhances slow inactivation of sodium channels, differing from many traditional sodium‑channel blockers that affect fast inactivation. This can provide an additional therapeutic option for patients who have inadequate seizure control with other antiepileptics, though individual response varies.

Lacosamide intravenous solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow any additional handling instructions provided by the manufacturer.

Lacosamide Fresenius Kabi is given as an intravenous infusion under medical supervision. The infusion rate and duration are set by the healthcare professional according to the patient’s clinical needs and the product’s prescribing information.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions, and rare cases of suicidal ideation. Patients should be monitored closely for these events, especially during treatment initiation.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking other medications that may cause additive CNS depression.